Maria C Sauerland
Overview
Explore the profile of Maria C Sauerland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
766
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pastore F, Gittinger H, Raab S, Tschuri S, Ksienzyk B, Konstandin N, et al.
Br J Haematol
. 2023 Jul;
202(6):1165-1177.
PMID: 37455345
Acute megakaryoblastic leukaemia (AMKL) is associated with poor prognosis. Limited information is available on its cytogenetics, molecular genetics and clinical outcome. We performed genetic analyses, evaluated prognostic factors and the...
2.
Pastore F, Pastore A, Rothenberg-Thurley M, Metzeler K, Ksienzyk B, Schneider S, et al.
Cancer
. 2022 Oct;
128(24):4213-4222.
PMID: 36271776
Background: Acute myeloid leukemia (AML) with initial hyperleukocytosis is associated with high early mortality and a poor prognosis. The aims of this study were to delineate the underlying molecular landscape...
3.
Herold T, Rothenberg-Thurley M, Grunwald V, Janke H, Goerlich D, Sauerland M, et al.
Leukemia
. 2020 Apr;
34(12):3161-3172.
PMID: 32231256
The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk stratification of acute myeloid leukemia have been widely adopted, but have not yet been validated in large cohorts of AML...
4.
Konstandin N, Pastore F, Herold T, Dufour A, Rothenberg-Thurley M, Hinrichsen T, et al.
Blood Adv
. 2018 Oct;
2(20):2724-2731.
PMID: 30337300
Biallelic mutations of the CCAAT/enhancer binding protein α () gene define a distinct genetic entity of acute myeloid leukemia (AML) with favorable prognosis. The presence of and mutations that are...
5.
Prassek V, Rothenberg-Thurley M, Sauerland M, Herold T, Janke H, Ksienzyk B, et al.
Haematologica
. 2018 Jun;
103(11):1853-1861.
PMID: 29903761
A cute myeloid leukemia is a disease of the elderly (median age at diagnosis, 65-70 years). The prognosis of older acute myeloid leukemia patients is generally poor. While genetic markers...
6.
Rothenberg-Thurley M, Amler S, Goerlich D, Kohnke T, Konstandin N, Schneider S, et al.
Leukemia
. 2018 Feb;
32(7):1598-1608.
PMID: 29472724
Some patients with acute myeloid leukemia (AML) who are in complete remission after induction chemotherapy harbor persisting pre-leukemic clones, carrying a subset of leukemia-associated somatic mutations. There is conflicting evidence...
7.
Metzeler K, Herold T, Rothenberg-Thurley M, Amler S, Sauerland M, Gorlich D, et al.
Blood
. 2016 Jun;
128(5):686-98.
PMID: 27288520
The clinical and prognostic relevance of many recently identified driver gene mutations in adult acute myeloid leukemia (AML) is poorly defined. We sequenced the coding regions or hotspot areas of...
8.
Niavarani A, Herold T, Reyal Y, Sauerland M, Buchner T, Hiddemann W, et al.
Br J Haematol
. 2015 Nov;
172(3):401-11.
PMID: 26597595
Wilms Tumor-1 (WT1) expression level is implicated in the prognosis of acute myeloid leukaemia (AML). We hypothesized that a gene expression profile associated with WT1 expression levels might be a...
9.
Pastore F, Kling D, Hoster E, Dufour A, Konstandin N, Schneider S, et al.
J Hematol Oncol
. 2014 Sep;
7:55.
PMID: 25214041
Background: The aim of this study was to analyze the long-term survival of AML patients with CEBPA mutations. Patients And Methods: We investigated 88 AML patients with a median age...
10.
Stelljes M, Krug U, Beelen D, Braess J, Sauerland M, Heinecke A, et al.
J Clin Oncol
. 2013 Dec;
32(4):288-96.
PMID: 24366930
Purpose: The majority of patients with acute myeloid leukemia (AML) who achieve complete remission (CR) relapse with conventional postremission chemotherapy. Allogeneic stem-cell transplantation (alloSCT) might improve survival at the expense...